Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype
{{output}}
Background: Severe eosinophilic asthma patients are at risk of exacerbations, which are associated with substantial costs. Mepolizumab lowers eosinophil levels and reduces exacerbation risk in severe eosinophilic asthma. We evalu... ...
